Axinn partner Chad Landmon was quoted in the Bloomberg BNA Pharmaceutical & Life Sciences News article, "Big Money, Rare Jury Reversal: Gilead’s $2.54B Victory Over Merck."

Click here to access the article. A subscription is required.